Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.idsociety.org › practice-guideline › covid-19-guideline-treatment-and-managementIDSA Guidelines on the Treatment and Management of Patients with...

   www.idsociety.org › practice-guideline › covid-19-guideline-treatment-and-management

   How do therapeutic agents perform when compared to each other to allow a tiered approach to treating patients with COVID-19? What is the comparative efficacy and safety of nirmatrelvir/ritonavir versus remdesivir, molnupiravir, and different anti-SARS-CoV-2 antibodies in mild-to-moderate disease?

   • Paxlovid

     This website uses cookies. We use cookies to ensure that we...

   • Antigen Testing

     December 20, 2022. Version 2.0.0 has been released and...

   • Serology

     Serologic tests for severe acute respiratory syndrome...

   • Training and Resources

     The primary objective of clinical practice guidelines is to...

   • AMR Guidance 2.0

     This guidance document provides recommendations to...

   • Infection Prevention & Control

     IDSA led a group of over forty organizations representing...

   • Evaluation and Management Services

     In 2022, changes were established for the office and...

   • State and Regional Societies

     Recognition. Listed as an “Affiliate of IDSA” on IDSA’s...

2. www.frontiersin.org › journals › immunologyA predictive model for disease severity among COVID-19 elderly...

   www.frontiersin.org › journals › immunology

   • Zapisane w pamięci cache

   29 lis 2023 · Immunological senescence and inflammation play a severe role in contributing to older patients who are more prone to severe outcomes of COVID-19 (1, 3). IgG antibodies, also known as immunoglobulin G, offer a prominent means of protection against contagious illnesses.

3. www.ncbi.nlm.nih.gov › pmc › articlesThe dynamic changes of serum IgM and IgG against SARS‐CoV‐2 in...

   www.ncbi.nlm.nih.gov › pmc › articles

   Our results suggested that the decline of IgM may be an indicator of virus clearance and recovered patients may have a robust immunity against reinfection within at least 3 months after illness onset.

4. www.ncbi.nlm.nih.gov › pmc › articlesEfficacy of COVID-19 treatments among geriatric patients: a...

   www.ncbi.nlm.nih.gov › pmc › articles

   1 cze 2022 · Hydroxychloroquine, dexamethasone, and remdesivir revealed greater side effects or inefficiency in geriatric patients with COVID-19. Favipiravir, bamlanivimab, baricitinib, and supportive therapy showed a decrease in viral load and improvement of clinical symptoms.

5. www.nature.com › articles › s41591/020/0897-1Antibody responses to SARS-CoV-2 in patients with COVID-19

   www.nature.com › articles › s41591/020/0897-1

   29 kwi 2020 · Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG...

6. www.cambridge.org › core › journalsDynamic changes of SARS-CoV-2 specific IgM and IgG among...

   www.cambridge.org › core › journals

   • Zapisane w pamięci cache

   The peak of IgG is higher from the young group (18–45 years old) at 4.968 (+1.609, −1.609) S/CO and existed for a longer time (about 2 weeks), while the elderly group (>60 years old) has a lower peak of IgG level at 3.675 (+2.423, −2.423) S/CO and a shorter time (about 1 week), which may be associated with the depression of immunity in ...

7. www.tandfonline.com › doi › fullTherapeutic antibodies for COVID-19: is a new age of IgM, IgA and...

   www.tandfonline.com › doi › full

   Strikingly, IgM-14 was more potent than IgG-14 in neutralizing SARS-CoV-2 VOCs, including Alpha, Beta and Gamma variants, as well as 21 other RBD mutants, indicating that IgM-14 is superior to IgG-14 in covering viral escape mutations.